3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
5
Myelodysplastic Syndromes
2
Pathologic Complete Response
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia
1
Interventions
blinatumomab
3
Cytarabine
3
venetoclax
2
revumenib
2
Daunorubicin
2
quizartinib
1
obinutuzumab
1
nilotinib
1
ivosidenib
1
etoposide phosphate
1
bosutinib
1
acalabrutinib
1
Mitoxantrone
1
Midazolam
1
Itraconazole
1
Imatinib Mesylate
1
Idarubicin
1
Gemtuzumab
1
Etoposide
1
Drug Therapy
1
Cobicistat
1
Azacitidine
1
Asparaginase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Leukemia
×
Azacitidine
×
Clear all
NCT03173248
2025-11-10
AGILE
Servier
Phase 3
Active not recruiting
146 enrolled
11 charts
1 FDA